(Q43726801)

26 November 2017

title

In vitro susceptibility study of BMS-284756 against Legionella species (English)

1 reference

26 November 2017

Dubois J

1

1 reference

26 November 2017

St-Pierre C

series ordinal

2

1 reference

26 November 2017

publication date

1 September 2001

1 reference

Diagnostic Microbiology and Infectious Disease

26 November 2017

published in

1 reference

26 November 2017

volume

41

1 reference

26 November 2017

issue

1-2

1 reference

26 November 2017

page(s)

79-82

1 reference

Treatment of community-acquired pneumonia

26 November 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0732-8893%2801%2900285-1

7 January 2021

In vitro activity of lomefloxacin (SC 47111 or NY-198) against isolates of Legionella spp.

1 reference

https://api.crossref.org/works/10.1016%2FS0732-8893%2801%2900285-1

7 January 2021

In-vitro activity of RP 59500, a new synergic antibacterial agent, against Legionella spp

1 reference

https://api.crossref.org/works/10.1016%2FS0732-8893%2801%2900285-1

7 January 2021

Comparative in vitro activity and post-antibiotic effect of gemifloxacin against Legionella spp.

1 reference

https://api.crossref.org/works/10.1016%2FS0732-8893%2801%2900285-1

7 January 2021

Legionella pneumophila

1 reference

https://api.crossref.org/works/10.1016%2FS0732-8893%2801%2900285-1

7 January 2021

Antibacterial spectrum of a novel des-fluoro(6) quinolone, BMS-284756

1 reference

https://api.crossref.org/works/10.1016%2FS0732-8893%2801%2900285-1

7 January 2021

Comparative antianaerobic activity of BMS 284756

1 reference

https://api.crossref.org/works/10.1016%2FS0732-8893%2801%2900285-1

7 January 2021

In-vitro activities of ciprofloxacin, levofloxacin, lomefloxacin, ofloxacin, pefloxacin, sparfloxacin and trovafloxacin against gram-positive and gram-negative pathogens from respiratory tract infections

1 reference

https://api.crossref.org/works/10.1016%2FS0732-8893%2801%2900285-1

7 January 2021

In vitro activity of newer fluoroquinolones for respiratory tract infections and emerging patterns of antimicrobial resistance: data from the SENTRY antimicrobial surveillance program

1 reference

https://api.crossref.org/works/10.1016%2FS0732-8893%2801%2900285-1

7 January 2021

Potential importance of Legionella species as etiologies in community acquired pneumonia (CAP)

1 reference

https://api.crossref.org/works/10.1016%2FS0732-8893%2801%2900285-1

7 January 2021

In vitro and in vivo efficacies of T-3811ME (BMS-284756) against Mycoplasma pneumoniae

1 reference

https://api.crossref.org/works/10.1016%2FS0732-8893%2801%2900285-1

7 January 2021

10.1016/S0732-8893(01)00285-1

Identifiers

DOI

1 reference

26 November 2017

1 reference